Background/Aims: Several guidelines for neuropathic pain management and various effective drugs are available; however, neuropathic pain remains undertreated. This retrospective study aimed to evaluate the efficacy of topical capsaicin 8% in peripheral neuropathic pain in a routine clinical setting. Methods: Therapeutic efficacy was evaluated through pain intensity, using numerical pain rating scale at baseline and 7–14 days after each treatment, and using pain treatment area (PTA) assessed immediately before each treatment. Results: A total of 43 patients with either post-herpetic neuralgia or post-traumatic/post-surgical neuropathic pain were enrolled. The median percentage reduction in numerical pain rating scale score and in PTA was –40.0 (–50.0 to –33.3; 95% CI, bootstrap) and –35.1 (–50.9 to 3.4; 95% CI, bootstrap), respectively. Pain intensity and PTA were equally improved and reduced in both treated conditions. Conclusion: This study suggests that topical capsaicin 8% reduces peripheral neuropathic pain as well as treatment pain area.

Keywords:
Capsaicin, Allodynia, Analgesic affect, Peripheral neuropathic pain
1.
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al: Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630–1635.
2.
Allegri M, Baron R, Hans G, Correa-Illanes G, Mayoral Rojals V, Mick G, et al: A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin 2016; 32: 377–384.
3.
Mick G, Baron R, Finnerup NB, Hans G, Kern KU, Brett B, et al: What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag 2012; 2: 71–77.
4.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al: -Pharmacotherapy for neuropathic pain in adults: a systematic review and -meta-analysis. Lancet Neurol 2015; 14: 162–173.
5.
Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113.e1188.
6.
Treede RD, Wagner T, Kern KU, Husstedt IW, Arendt G, Birklein F, et al: Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Curr Med Res Opin 2013; 29: 527–538.
7.
Lyer PW: Medical Aspects of Pain and Suffering, USA, 2003.
8.
Gewandter JS, Dworkin RH, Turk DC, Farrar JT, Fillingim RB, Gilron I, et al: Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain 2010; 156: 1184–1197.
9.
Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL: Defining the clinically important difference in pain outcome measures. Pain 2000; 88: 287–294.
10.
Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, et al: Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010; 149: 177–193.
11.
Zar JH: Biostatistical Analisis: Prentice Hall, 2010.
12.
Barnett AG, van der Pols JC, Dobson AJ: Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005; 34: 215–220.
13.
Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr, Rauck R, et al: NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008; 7: 1106–1112.
14.
Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, et al: A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011; 12: 99–109.
15.
Mou J, Paillard F, Turnbull B, Trudeau J, Stoker M, Katz NP: Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. Clin J Pain 2014; 30: 286–294.
16.
Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF: A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 2010; 11: 972–982.
17.
Dos Reis FJ, de Barros E Silva V, de Lucena RN, Mendes Cardoso BA, Nogueira LC: Measuring the pain area: an intra- and inter-rater reliability study using image analysis software. Pain Pract 2016; 16: 24–30.
18.
Saarto T, Wiffen PJ: Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2010; 81: 1372–1373.
19.
Whitney CW, Von Korff M: Regression to the mean in treated versus untreated chronic pain. Pain 1992; 50: 281–285.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.